



Vicore update on the AIR phase 2 trial in idiopathic pulmonary fibrosis

- The previously reported February interim analysis will be presented as a late breaker at the ERS congress
- Observations of continued stabilization and increase in lung capacity
- A second interim analysis and update on the development program are planned for Q4 2022

Gothenburg, September 2, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), gives a short update and informs about upcoming events in the AIR trial, a phase 2 trial in idiopathic pulmonary fibrosis (IPF).

As previously announced, on September 4 Professor Toby Maher, Keck School of Medicine at the University of Southern California, will give a late breaker presentation of the February interim analysis from the AIR trial at the European Respiratory Society International Congress. Vicore is monitoring the study closely and observations show that there are no changes from February, with a continued early stabilization and an increase of lung capacity from 18 weeks to 36 weeks of treatment. The company expects to perform a second interim analysis in Q4 and to present an outline of the upcoming development program for C21 in idiopathic pulmonary fibrosis (IPF).

For further information, please contact:

Carl-Johan Dalsgaard, CEO

Phone: +46 70 975 98 63

E-mail: carl-johan.dalsgaard@vicorepharma.com

This information was submitted for publication on September 2, 2022 at 08:00 CET.

About Vicore Pharma Holding AB (publ)

Vicore is a clinical-stage pharmaceutical company focused on developing innovative medicines in severe diseases where the Angiotensin II type 2 receptor (AT2R) plays an important role. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF), pulmonary artery hypertension (PAH) and COVID-19. VP02 is a new formulation and delivery route of thalidomide and focuses on the underlying disease and the severe cough associated with IPF. VP03 includes the development of new AT2 receptor agonists. VP04 develops a clinically validated digital therapeutic for IPF patients.

The company's shares (VICO) are listed on Nasdaq Stockholm's main market. For more information, see www.vicorepharma.com.